How GLP-1 Actually Works

Watch the full breakdown (about 25 minutes) — or read it below.

The real science behind semaglutide and tirzepatide — the wiring, the discovery, the trade‑offs, and what to do about them. Not fear. Not hype. Just physiology, explained clearly.

First: why losing weight is biologically hard

Here's the truth almost no one hears from their doctor. Obesity is not a moral failure — it's an evolutionary success.

For 99.9% of human history, starvation, not overeating, was the number one cause of death. The people who stored fat most efficiently survived; the ones who burned through calories didn't. You are the descendant of the world's best fat‑storers. Your biology is optimized to survive scarcity — but you live in an age of Uber Eats and DoorDash. Your genes still expect famine.

Biologists call this an evolutionary mismatch: ancient biology, brand‑new environment. That conflict is why weight loss feels like swimming against the current. But it gets more interesting once you understand the wiring.

The wiring: your two hormones

Deep in your brain sits the hypothalamus — the survival center that defends your body‑fat set point with military precision. It uses two hormones to do it.

  • Ghrelin — the gas pedal. Made by your stomach when it's empty. It travels up the vagus nerve and says we need food. It's primal, overpowering, and documented to override willpower completely.

  • Leptin — the brake. Made by your fat cells. When stores are full, it tells the brain we have enough, stop eating.

Here's the problem: in obesity, the brain becomes leptin resistant — the way you stop smelling perfume after a few minutes. So someone can have 100+ pounds of energy stored on their body and still feel genuinely hungry. This isn't weakness. It's wiring. GLP‑1 medications override this broken circuit — but the discovery didn't begin in a lab.

The discovery: a lizard in the desert

In the 1980s, scientists noticed something strange. Inject sugar into the bloodstream and the insulin response is small. Drink the same sugar and the insulin response is huge. Why? Because the gut warns the body in advance — intestinal L‑cells release a hormone called GLP‑1.

GLP‑1 does three things at once: it preps the pancreas for insulin, it slows the stomach, and it tells the brain you're satisfied. This is the incretin effect. The catch: natural GLP‑1 breaks down in about two minutes, chewed up by an enzyme called DPP‑4. To turn it into a drug, scientists had to outsmart DPP‑4.

The answer came from the Gila monster — a venomous desert lizard that eats only a few times a year. In 1992, Dr. John Eng discovered its venom contains a molecule, Exendin‑4, that binds the same receptor as GLP‑1 but doesn't get sliced apart by DPP‑4. It survives. That was the blueprint for the first GLP‑1 medications.

The engineering: a hormone that lasts a week

Modern chemists took that idea and built something far more powerful. Semaglutide — the molecule in Ozempic and Wegovy — does two brilliant things:

  1. It changes one amino acid, so DPP‑4 can't cut it.

  2. It attaches a fatty‑acid tail that binds to albumin, a large protein that circulates in your blood for about a week.

Think of albumin as a cruise ship: semaglutide attaches and coasts through your bloodstream for days. A hormone that should last two minutes now lasts 168 hours — which is what makes a once‑weekly injection possible.

The upgrade: dual action

Then came tirzepatide (Mounjaro and Zepbound), which doesn't activate one receptor — it activates two: GLP‑1 and GIP. GLP‑1 quiets appetite; GIP helps with glucose control and tolerability. That synergy allows deeper appetite reduction, often with better tolerance for many people — which is why tirzepatide tends to produce greater average weight loss than semaglutide in clinical trials. (Though, as always, individual results vary.)

The trade‑offs (this is biology, not fear)

Nobody explains this part clearly, so I will. None of this is meant to scare you — it's the physiology behind the risks, so you can make an informed decision.

  • These medications work partly by slowing how fast your stomach empties. For most people that's mild and therapeutic. For some — especially at higher doses — it can mean nausea, reflux, bloating, and early fullness, usually manageable with dose adjustment. Rarely, the slowing is significant enough that a clinician evaluates for delayed gastric emptying (gastroparesis). Rare, but real.

  • If your stomach empties slowly, you may have food in it even after fasting — and anesthesia switches off the reflexes that protect your airway. That's why anesthesiologists updated their guidelines in 2023. It doesn't make anesthesia unsafe; it means your anesthesiologist must know you're on a GLP‑1. Awareness is prevention.

  • Overall risk appears low, but the caution exists for a reason. People with a history of pancreatitis, very high triglycerides, or heavy alcohol use carry baseline risk. Persistent, severe abdominal pain is something a physician should evaluate.

  • Every GLP‑1 carries a boxed warning about thyroid C‑cell tumors — in rodents, which have far more of these receptors than humans do. Human studies haven't shown a clear increase so far. Still, anyone with a personal or family history of medullary thyroid cancer or MEN2 is advised not to take these — not because harm is proven, but because we don't yet have 20‑year data. That's what good medicine does: it respects known genetic vulnerability.

  • When you lose weight fast by any method, you lose fat and muscle. On a GLP‑1, appetite drops, protein often drops with it, and training gets harder. Why it matters: muscle is the engine of your metabolism, your main site of glucose disposal, and a predictor of longevity. Less muscle means a slower metabolism, which means easier regain. This is common without a strategy — and entirely preventable with one.

  • Not the drug damaging your skin — it's rapid fat loss. When facial fat pads shrink quickly, skin doesn't always retract at the same pace. It's volume change. It's physics, not toxicity. Slower, steadier loss (plus protein and strength work) preserves facial structure better.

  • GLP‑1 receptors sit in the brain's reward pathways. Many people feel calmer and less food‑obsessed — a real benefit, especially with emotional or binge eating. But a smaller group describes something else: muted motivation, less spark, a "grayscale" feeling. Not sadness exactly — reduced reward drive. If you feel flatter than expected, your clinician wants to know.

  • The honest answer: many people regain weight without a strategy — not because they failed, but because biology rebounds. When the medication leaves, ghrelin doesn't just return, it overshoots; appetite comes back before fullness signals do; and reduced muscle means a smaller engine. Fat returns faster than muscle rebuilds — a pattern researchers call preferential adipose regain. This is chemistry and physics. And physics can be engineered.

The bottom line

GLP‑1 medications taught us something profound: obesity is biology, not a moral issue. For many people these drugs reduce cardiovascular risk, improve metabolic health, and quiet decades of obsessive food thoughts. For others, they're a bridge — a tool to build new habits while biology stabilizes. And for some, there are real trade‑offs that need careful navigation.

There's no one‑size‑fits‑all answer. There's only informed consent, evidence‑based decisions, and respect for how complex the human body is.

You are not weak. You are not broken. You are not a moral failure. You're a human being living in an environment your biology was never designed for — and now you finally have a tool, paired with a protocol that honors your physiology.

The protocols: how to protect your biology

This is the path forward — supported by peer‑reviewed research, and the core of how I work with patients. None of this replaces a conversation with your own physician — start there. But here's the framework.

  • When appetite is low, protein is the first thing to disappear and the last thing your body should lose. Aim for adequate daily protein, with your clinician guiding your specific target. If solid food feels heavy, easier sources include whey isolate, collagen, essential amino acids, dairy, and egg‑white protein. Protein is your muscle insurance — and muscle is your metabolic insurance.

  • No drug, supplement, or hack replaces mechanical load on muscle. Even two days a week of resistance training meaningfully reduces lean‑mass loss during weight loss. This isn't about looking fit — it's metabolic preservation.

  • If you ever come off these medications — in coordination with your doctor — don't stop abruptly. A sudden drop in GLP‑1 signaling triggers a rapid rebound in hunger. A gradual taper lets your hunger hormones recalibrate, your satiety signals normalize, and your habits hold. Give your body time to readjust.

  • As doses come down and your stomach starts signaling hunger again, high‑volume, low‑calorie foods (oats, beans, berries, vegetables, lentils, psyllium) stretch the stomach's mechanical receptors. This is how you hand the baton from the drug's chemical satiety to your stomach's mechanical satiety.

  • If your spark dims — less interest in hobbies, life feeling flatter — tell your physician. It may be dose‑related or transient, or it may need adjustment. Your emotional landscape matters as much as your metabolic one.

Want this applied to your body?

A class can teach you how the science works. It can't read your labs or know your history — that's a conversation.

See if you're a candidate
Book a consult

This page and the accompanying video are educational and do not diagnose, prescribe, or replace care from a licensed clinician. GLP‑1 medications are prescription drugs with real risks and side effects, prescribed only after a full medical evaluation, when medically appropriate. The protocols described are general education, not a personal treatment plan — talk to your own physician before starting, changing, or stopping any medication. Individual results vary.